BACKGROUND: Antazoline is an old antihistaminic and new antiarrhythmic agent with unknown mechanisms of action which recently has been shown to effectively terminate atrial fibrillation. The aim of study was to examine the effects of antazoline on hemodynamic and ECG parameters. METHODS: Antazoline was given intravenously in three 100 mg boluses to 10 healthy volunteers (four males, mean age 40 + 11 years). Hemodynamic and ECG parameters were measured using impedance cardiography [systolic (sBP), diastolic (dBP), mean (mBP) blood pressure, stroke volume (SV), cardiac output (CO), total peripheral resistance (TPR) and heart rate (HR), P wave, PR interval, QRS complex, QT and corrected QT (QTcF) interval]. Plasma concentration of antazoline was also measured. RESULTS: Antazoline caused significant prolongation of P wave, QRS as well as QT and QTcF (101 ± 10 vs 110 ± 16 ms, p < .05, and 101 ± 12 vs 107 ± 12 ms, p < .05, 399 ± 27 vs 444 ± 23 ms, p < .05, and 403 ± 21 vs 448 ± 27 ms, p < .05, respectively). Also, a significant decrease in SV was noted (94.9 ± 21.8 vs 82.4 ± 19.6 ml, p < .05). A significant correlation between changes in plasma drug concentration and changes in CO, HR, and dBP was found. CONCLUSIONS: Antazoline impairs slightly hemodynamics, significantly reducing SV. Significant prolongation of P wave and QRS duration corresponds to drug-induced prolongation of conduction, whereas QT prolongation represents drug-induced prolongation of repolarization.
BACKGROUND:Antazoline is an old antihistaminic and new antiarrhythmic agent with unknown mechanisms of action which recently has been shown to effectively terminate atrial fibrillation. The aim of study was to examine the effects of antazoline on hemodynamic and ECG parameters. METHODS:Antazoline was given intravenously in three 100 mg boluses to 10 healthy volunteers (four males, mean age 40 + 11 years). Hemodynamic and ECG parameters were measured using impedance cardiography [systolic (sBP), diastolic (dBP), mean (mBP) blood pressure, stroke volume (SV), cardiac output (CO), total peripheral resistance (TPR) and heart rate (HR), P wave, PR interval, QRS complex, QT and corrected QT (QTcF) interval]. Plasma concentration of antazoline was also measured. RESULTS:Antazoline caused significant prolongation of P wave, QRS as well as QT and QTcF (101 ± 10 vs 110 ± 16 ms, p < .05, and 101 ± 12 vs 107 ± 12 ms, p < .05, 399 ± 27 vs 444 ± 23 ms, p < .05, and 403 ± 21 vs 448 ± 27 ms, p < .05, respectively). Also, a significant decrease in SV was noted (94.9 ± 21.8 vs 82.4 ± 19.6 ml, p < .05). A significant correlation between changes in plasma drug concentration and changes in CO, HR, and dBP was found. CONCLUSIONS:Antazoline impairs slightly hemodynamics, significantly reducing SV. Significant prolongation of P wave and QRS duration corresponds to drug-induced prolongation of conduction, whereas QT prolongation represents drug-induced prolongation of repolarization.
Authors: Roman Piotrowski; Tomasz Kryński; Jakub Baran; Piotr Futyma; Sebastian Stec; Piotr Kułakowski Journal: Cardiol J Date: 2013-08-30 Impact factor: 2.737
Authors: J Fortin; W Habenbacher; A Heller; A Hacker; R Grüllenberger; J Innerhofer; H Passath; Ch Wagner; G Haitchi; D Flotzinger; R Pacher; P Wach Journal: Comput Biol Med Date: 2005-08-29 Impact factor: 4.589
Authors: Katarzyna Zgoła; Piotr Kułakowski; Aleksandra Czepiel; Maciej Świątkowski; Ewa Makowska; Elżbieta Błachnio; Małgorzata Soszyńska; Magdalena Misiewicz Journal: Kardiol Pol Date: 2014-05-20 Impact factor: 3.108
Authors: Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy Journal: Circulation Date: 2014-03-28 Impact factor: 29.690
Authors: Michał M Farkowski; Aleksander Maciąg; Małgorzata Żurawska; Mariusz Pytkowski; Ilona Kowalik; Jacek Woźniak; Maciej Sterliński; Hanna Szwed Journal: Pol Arch Med Wewn Date: 2016-06-24
Authors: Michal M Farkowski; Aleksander Maciag; Ilona Kowalik; Marek Konka; Hanna Szwed; Mariusz Pytkowski Journal: Br J Clin Pharmacol Date: 2019-05-23 Impact factor: 4.335
Authors: Bartłomiej Jacek Bińkowski; Marcin Makowski; Paweł Kubiński; Andrzej Lubiński Journal: Cardiovasc Drugs Ther Date: 2018-04 Impact factor: 3.727
Authors: Joanna Giebułtowicz; Natalia Korytowska; Monika Sobiech; Sebastian Polak; Barbara Wiśniowska; Roman Piotrowski; Piotr Kułakowski; Piotr Luliński Journal: Int J Mol Sci Date: 2021-04-01 Impact factor: 5.923
Authors: Beata Ceynowa-Sielawko; Maciej T Wybraniec; Aleksandra Topp-Zielińska; Aleksander Maciąg; Dawid Miśkowiec; Paweł Balsam; Maciej Wójcik; Wojciech Wróbel; Michał M Farkowski; Edyta Ćwiek-Rębowska; Krzysztof Ozierański; Robert Błaszczyk; Karolina Bula; Tomasz Dembowski; Michał Peller; Bartosz Krzowski; Wojciech Wańha; Marek Koziński; Jarosław D Kasprzak; Hanna Szwed; Katarzyna Mizia-Stec; Marek Szołkiewicz Journal: Int J Environ Res Public Health Date: 2022-04-17 Impact factor: 3.390
Authors: Maciej T Wybraniec; Wojciech Wróbel; Katarzyna Wilkosz; Karolina Wrona; Karolina Bula; Katarzyna Mizia-Stec Journal: J Am Heart Assoc Date: 2018-10-16 Impact factor: 5.501
Authors: Barbara Wiśniowska; Joanna Giebułtowicz; Roman Piotrowski; Piotr Kułakowski; Sebastian Polak Journal: Pharmaceuticals (Basel) Date: 2022-03-20